2012, A Clinical Outcomes study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in subjects with moderate Chronic Obstructive Pulmonary Disease(COPD) and a history of or at Increased risk for cardiovascular Disease. PARELEX Number 110812, 090828 (SUMMIT STUDY)
2012, Protocol SAS115399 : A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionat In the treatment of Adolescent and Adult Subjects wih Asthma (ASMALABA)
2012, Outgoing A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy with Racotumomab Plus Best Support Treatment in Patients with Advanced nonsquamous Non-Small Cell Lung Center
2011, A randomized, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study of budesonide/folmoterol(Symbicort® Turbuhaler®160/4.5μg/inhalation, 2 inhalation twice daily) added to tiotropium(Spiriva™18μg/inhalation, 1 inhalation once daily)compared with tiotropium (Spiriva®18μg/inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (COPD) patients. (SECURE I)
2008, Cross sectional study of prevalence and distribution of cigarette smoking habits in Indonesian male hospital patients with non-tobacco-related admissions diagnoses
2006, An open label, randomized, parallel group, multicentre, phase III study to assess efficacy, safety and tolerability of gefitinib (IRESSATM) (250 mg tablet) versus carboplatin/paclittaxel doublet chemotheraphy as first-line treatment in selected patients with advanced (stage IIIB or IV) non – small cell lung cancer (NSCLC) in Asia (IPASS)
2004, Efficacy and safety of Symbicort “Turbuhaler” 160/4.5 μg/Inhalation, two inhalations twice daily plus as-needed compared with seretideTM DIiskus TM 50/500 μg/inhalation, one inhalation twice daily plus terbutalin Turbuhaler 0,4 mg/inhalation as-needded-a 6-month, randomised,double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma (AHEAD)